North America Antimicrobial Susceptibility Testing Market - Indsutry Trends and Forecast to 2028

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 65
1.1 OBJECTIVES OF THE STUDY 65
1.2 MARKET DEFINITION 65
1.3 OVERVIEW OF NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 65
1.4 LIMITATIONS 67
1.5 MARKETS COVERED 67
2 MARKET SEGMENTATION 70
2.1 MARKETS COVERED 70
2.2 GEOGRAPHICAL SCOPE 71
2.3 YEARS CONSIDERED FOR THE STUDY 72
2.4 CURRENCY AND PRICING 72
2.5 DBMR TRIPOD DATA VALIDATION MODEL 73
2.6 MULTIVARIATE MODELLING 76
2.7 PRODUCT TYPE LIFELINE CURVE 77
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 78
2.9 DBMR MARKET POSITION GRID 79
2.10 MARKET APPLICATION COVERAGE GRID 80
2.11 VENDOR SHARE ANALYSIS 81
2.12 SECONDARY SOURCES 82
2.13 ASSUMPTIONS 82
3 EXECUTIVE SUMMARY 83
4 PREMIUM INSIGHTS 85
5 MARKET OVERVIEW 86
5.1 DRIVERS 88
5.1.1 RISING EPIDEMIC AND PANDEMIC OUTBREAK 88
5.1.2 GROWING HEALTHCARE EXPENDITURE 88
5.1.3 INCREASING NORTH AMERICA PREVALENCE OF INFECTIOUS DISEASES 89
5.1.4 INCREASING PREVALENCE OF MULTI-DRUG RESISTANCE ORGANISM 89
5.1.5 GROWING INFRASTRUCTURE FACILITIES 89
5.1.6 HIGHER ADOPTION OF TECHNOLOGICALLY ADVANCED SUSCEPTIBILITY TESTING METHODS 90
5.2 RESTRAINTS 90
5.2.1 STRINGENT GOVERNMENT REGULATIONS 90
5.2.2 HIGH COSTS 91
5.2.3 SHORTAGE OF SKILLED PERSONNEL 91
5.3 OPPORTUNITIES 92
5.3.1 TECHNOLOGICAL ADVANCEMENTS 92
5.3.2 INVESTMENTS IN HEALTHCARE INFRASTRUCTURE 92
5.3.3 INFRASTRUCTURE OF NEW GENOMIC IDENTIFICATION METHODS 93
5.3.4 INCREASE IN FUNDING 93
5.4 CHALLENGES 94
5.4.1 EMERGENCE OF LOCAL PLAYER IN THE MARKETS 94
5.4.2 LACK OF CLINICAL DATA FROM FDA 94
5.4.3 DELAYS BETWEEN CLINICAL BREAKPOINT AND ITS CLEARANCE 94
6 IMPACT OF COVID-19 ON NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 95
6.1 IMPACT ON PRICE 95
6.2 IMPACT ON DEMAND 95
6.3 IMPACT ON SUPPLY 95
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19 96
6.5 CONCLUSION: 96
7 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE 97
7.1 OVERVIEW 98
7.2 INSTRUMENTS 101
7.2.1 MANUAL 102
7.2.1.1 MINIATURIZED IDENTIFICATION SYSTEMS 102
7.2.1.2 SUSCEPTIBILITY TESTING DISCS 102
7.2.1.2.1 HEXA DISCS 103
7.2.1.2.1.1 GRAM NEGATIVE ORGANISM 103
7.2.1.2.1.2 GRAM POSITIVE ORGANISM 104
7.2.1.2.1.3 GENERAL PURPOSE 104
7.2.1.2.1.4 ANAEROBIC BACTERIA 104
7.2.1.2.1.5 ANTIFUNGAL 104
7.2.1.2.1.6 OTHERS 104
7.2.1.2.2 OCTA DISCS 104
7.2.1.2.2.1 GRAM NEGATIVE ORGANISM 105
7.2.1.2.2.2 GRAM POSITIVE ORGANISM 105
7.2.1.2.2.3 UTI ORGANISMS 105
7.2.1.2.2.4 PSEUDOMONAS 105
7.2.1.2.2.5 GENERAL PURPOSE 105

7.2.1.2.3 DODECA DISCS 106
7.2.1.2.3.1 GENERAL PURPOSE 106
7.2.1.2.3.2 GRAM NEGATIVE ORGANISM 106
7.2.1.2.3.3 GRAM POSITIVE ORGANISM 106
7.2.1.2.3.4 PSEUDOMONAS 106
7.2.1.2.3.5 UTI ORGANISMS 107
7.2.1.2.4 ICOSA DISCS 107
7.2.1.2.4.1 GENERAL PURPOSE 107
7.2.1.2.4.2 PSEUDOMONAS 107
7.2.1.2.4.3 UTI ORGANISMS 107
7.2.1.3 MIC STRIPS 107
7.2.1.3.1 COMBINATION ANTIBACTERIAL 108
7.2.1.3.2 DUAL ANTIBACTERIAL 108
7.2.1.3.3 MULTIPLE ANTIBACTERIAL 108
7.2.1.3.4 SINGLE ANTIBACTERIAL 108
7.2.1.3.5 ANTIFUNGAL 108
7.2.2 AUTOMATED IDENTIFICATION AND SUSCEPTIBILITY TESTING SYSTEM 108
7.3 CONSUMABLES & ACCESSORIES 109
7.3.1 REAGENT AND BROTHS 110
7.3.2 MEDIA 110
7.3.3 SUSCEPTIBILITY PANELS 110
7.3.4 OTHERS 110
7.4 SERVICES & SOFTWARE 110
8 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,BY METHOD 112
8.1 OVERVIEW 113
8.2 DISK DIFFUSION 116
8.3 DILUTION 116
8.4 MASS SPECTROMETRY METHOD 117
8.5 E-TESTS 117
8.6 GENOTYPIC METHODS 118
8.7 OTHERS 119
9 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE 120
9.1 OVERVIEW 121
9.2 ANTIBACTERIAL TESTING 124
9.3 ANTIFUNGAL TESTING 124
9.4 OTHERS 125

10 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION 126
10.1 OVERVIEW 127
10.2 CLINICAL DIAGNOSTICS 130
10.3 DRUG DISCOVERY AND DEVELOPMENT 131
10.4 EPIDEMIOLOGY 131
10.5 OTHERS 132
11 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER 134
11.1 OVERVIEW 135
11.2 HOSPITALS 138
11.3 DIAGNOSTIC LABORATORIES 139
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 140
11.5 CONTRACT RESEARCH ORGANISATION 140
11.6 RESEARCH CENTRES & ACADEMIC INSTITUTES 142
11.7 OTHERS 142
12 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY DISTRIBUTION CHANNEL 145
12.1 OVERVIEW 146
12.2 DIRECT SALES 149
12.3 RETAIL SALES 150
12.4 THIRD PARTY DISTRIBUTOR 150
13 NORTH AMERICA ANTIMICROBIAL SUCEPTIBILITY TESTING MARKET BY GEOGRAPHY 152
13.1 OVERVIEW 152
13.2 NORTH AMERICA 156
13.2.1 U.S. 164
13.2.2 CANADA 169
13.2.3 MEXICO 174
14 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY LANDSCAPE 179
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 179
15 SWOT 180

16 COMPANY PROFILE 181
16.1 THERMO FISHER SCIENTIFIC INC. 181
16.1.1 COMPANY SNAPSHOT 181
16.1.2 REVENUE ANALYSIS 181
16.1.3 COMPANY SHARE ANALYSIS 182
16.1.4 PRODUCT PORTFOLIO 182
16.1.5 RECENT DEVELOPMENTS 183
16.2 BIOMRIEUX SA 184
16.2.1 COMPANY SNAPSHOT 184
16.2.2 REVENUE ANALYSIS 184
16.2.3 COMPANY SHARE ANALYSIS 185
16.2.4 PRODUCT PORTFOLIO 185
16.2.5 RECENT DEVELOPMENTS 185
16.3 DANAHER 187
16.3.1 COMPANY SNAPSHOT 187
16.3.2 REVENUE ANALYSIS 187
16.3.3 COMPANY SHARE ANALYSIS 188
16.3.4 PRODUCT PORTFOLIO 188
16.3.5 RECENT DEVELOPMENTS 189
16.4 MERCK KGAA 191
16.4.1 COMPANY SNAPSHOT 191
16.4.2 REVENUE ANALYSIS 191
16.4.3 COMPANY SHARE ANALYSIS 192
16.4.4 PRODUCT PORTFOLIO 192
16.4.5 RECENT DEVELOPMENTS 192
16.5 ACCELERATE DIAGNOSTICS, INC. 194
16.5.1 COMPANY SNAPSHOT 194
16.5.2 REVENUE ANALYSIS 194
16.5.3 PRODUCT PORTFOLIO 195
16.5.4 RECENT DEVELOPMENTS 195
16.6 ALIFAX S.R.L. 196
16.6.1 COMPANY SNAPSHOT 196
16.6.2 PRODUCT PORTFOLIO 196
16.6.3 RECENT DEVELOPMENTS 197
16.7 BACTERIOSCAN, INC. 198
16.7.1 COMPANY SNAPSHOT 198
16.7.2 PRODUCT PORTFOLIO 198
16.7.3 RECENT DEVELOPMENTS 198

16.8 BD 200
16.8.1 COMPANY SNAPSHOT 200
16.8.2 REVENUE ANALYSIS 200
16.8.3 PRODUCT PORTFOLIO 201
16.8.4 RECENT DEVELOPMENTS 201
16.9 BIO-RAD LABORATORIES, INC. 203
16.9.1 COMPANY SNAPSHOT 203
16.9.2 REVENUE ANALYSIS 203
16.9.3 PRODUCT PORTFOLIO 204
16.9.4 RECENT DEVELOPMENTS 204
16.10 CREATIVE DIAGNOSTICS 205
16.10.1 COMPANY SNAPSHOT 205
16.10.2 PRODUCT PORTFOLIO 205
16.10.3 RECENT DEVELOPMENTS 205
16.11 ERBA GROUP 207
16.11.1 COMPANY SNAPSHOT 207
16.11.2 PRODUCT PORTFOLIO 207
16.11.3 RECENT DEVELOPMENTS 207
16.12 GENEFLUIDICS, INC. 209
16.12.1 COMPANY SNAPSHOT 209
16.12.2 PRODUCT PORTFOLIO 209
16.12.3 RECENT DEVELOPMENTS 209
16.13 HIMEDIA LABORATORIES 211
16.13.1 COMPANY SNAPSHOT 211
16.13.2 PRODUCT PORTFOLIO 211
16.13.3 RECENT DEVELOPMENTS 211
16.14 LIOFILCHEM S.R.L. 213
16.14.1 COMPANY SNAPSHOT 213
16.14.2 PRODUCT PORTFOLIO 213
16.14.3 RECENT DEVELOPMENTS 213
16.15 MAST GROUP LTD. 215
16.15.1 COMPANY SNAPSHOT 215
16.15.2 PRODUCT PORTFOLIO 215
16.15.3 RECENT DEVELOPMENTS 215
16.16 MERLIN GESELLSCHAFT FUR MICROBIOLOGISCHE DIAGNOSTIKA MBH 217
16.16.1 COMPANY SNAPSHOT 217
16.16.2 PRODUCT PORTFOLIO 217
16.16.3 RECENT DEVELOPMENTS 217

16.17 NUMEDII, INC. 219
16.17.1 COMPANY SNAPSHOT 219
16.17.2 TECHNOLOGY PORTFOLIO 219
16.17.3 RECENT DEVELOPMENTS 219
16.18 ROSCO DIAGNOSTICA A/S 221
16.18.1 COMPANY SNAPSHOT 221
16.18.2 PRODUCT PORTFOLIO 221
16.18.3 RECENT DEVELOPMENT 221
16.19 SYNBIOSIS 222
16.19.1 COMPANY SNAPSHOT 222
16.19.2 PRODUCT PORTFOLIO 222
16.19.3 RECENT DEVELOPMENTS 222
16.20 ZHUHAI DL BIOTECH CO., LTD 224
16.20.1 COMPANY SNAPSHOT 224
16.20.2 PRODUCT PORTFOLIO 224
16.20.3 RECENT DEVELOPMENT 224
17 QUESTIONNAIRE 225
18 RELATED REPORTS 228